<DOC>
	<DOCNO>NCT00482274</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well docetaxel work treat patient relapsed prostate cancer .</brief_summary>
	<brief_title>Docetaxel Treating Patients With Relapsed Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete response rate patient biochemically-relapsed , hormone-sensitive prostate cancer treat docetaxel . Secondary - Determine time PSA recurrence patient receive treatment . - Determine time metastatic disease patient receive treatment . - Determine time androgen independent state patient receive treatment . - Determine time death cause patient receive treatment . OUTLINE : This open label study . Patients receive docetaxel IV 60 minute day 1 . Treatment repeat every 21 day 4-6 course absence unacceptable toxicity disease progression . After completion study therapy , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Criteria Patient eligibility Inclusion criterion 1 . Histologically confirm adenocarcinoma prostate . 2 . Prior primary therapy prostate cancer , include radical prostatectomy , external beam radiation therapy , brachytherapy . 3 . Serum PSA &gt; 0.2 ng/dL follow 8 month androgen deprivation therapy nadir PSA &gt; 0.2 ng/dL least 1 subsequent PSA value high level , prior 8 month . 4 . Serum testosterone &lt; 50 ng/ml . 5 . No evidence metastases bone scan . 6 . No evidence metastases CT scan abdomen pelvis . 7 . ECOG performance status &lt; 2 . 8 . Laboratory criterion entry : absolute neutrophil count ≥ 1.2 K/cu mm , platelet ≥ 100 K/cu mm , serum bilirubin ≤ upper limit normal ( ULN ) , SGOT SGPT ≤ 1.5 time institutional ULN alkaline phosphatase ≤ ULN , alkaline phosphatase ≤ 5 time ULN SGOT SGPT ≤ ULN , serum creatinine ≤ 2 time institutional ULN . 9 . Signed informed consent . Exclusion Criteria 1 . A second active malignancy last 5 year , except adequately treat nonmelanoma skin cancer . 2 . Life expectancy &lt; 3 month . 3 . Grade 2 high peripheral neuropathy . 4 . Prior investigational agent within past 28 day . 5 . Less 10 % decrease ( continued rise ) PSA response initial androgendeprivation therapy . 6 . More 12 month since initiation androgendeprivation therapy . 7 . Prior docetaxel chemotherapy . 8 . Patients recently ( within 28 day ) start corticosteroid , exception inhale topical steroid . Patients stable dos systemic corticosteroid eligible .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>